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Abstract
Background: Buruli ulcer (BU), also known as Mycobacterium ulcerans disease, is the third most common
mycobacterial disease worldwide. Although BU disease has been diagnosed among Nigerians in neighbouring
West African countries, data on the burden of the disease in Nigeria itself are scanty. This study aimed to assess
the magnitude and epidemiology of BU in the South South region of Nigeria.
Methods: We conducted a cross-sectional survey in the Ogoja territory (comprising 31 communities). We
undertook sensitisation programmes centred on BU in 10 of the communities. Participants were asked to identify
community members with long-standing ulcers, who were then invited for evaluation. We also contacted
traditional healers to refer their clients who had non-healing ulcers. All suspected cases had a full clinical
evaluation and laboratory testing. Confirmed cases were given treatment in a referral hospital in the territory.
Results: We diagnosed 41 clinical BU cases; 36 (87.8 %) of which were confirmed by quantitative polymerase
chain reaction (qPCR). These 36 PCR-confirmed cases were diagnosed in a total population of 192,169 inhabitants.
Therefore, the estimated crude prevalence of BU was 18.7 per 100,000 population, varying from 6.0 to 41.4 per
100,000 in the districts surveyed. The majority (66.7 %) of the cases were females. About 92 % of the BU lesions
were located on the patients’ extremities. No differences were observed between the sexes in terms of the location
of the lesions. The age of the patients ranged from four to 60 years, with a median age of 17 years. All 35 (100 %)
patients who consented to treatment completed chemotherapy as prescribed. Of the treated cases, 29 (82.9 %)
needed and received surgery. All cases healed, but 29 (82.9 %) had some limitations in movement. Healing with
limitations in movement occurred in 18/19 (94.7 %) and 8/10 (80.0 %) of patients with lesions >15 cm (Category III)
and 6–15 cm in diameter (Category II), respectively. The median duration of treatment was 130 (87–164) days for
children and 98 (56–134) days for adults (p = 0.15).
Conclusions: In Nigeria, BU is endemic but its severity is underestimated—at least in the study setting. There is a
need to identify and map BU endemic regions in Nigeria. A comprehensive BU control programme is also urgently
needed.
Keywords: Buruli ulcer, Mycobacterium ulcerans, Epidemiology, Case finding, Endemicity, Ogoja, Cross River State,
Nigeria
* Correspondence: ukwajakingsley@yahoo.co.uk
1Department of Medicine, Federal Teaching Hospital , FMC Rd, Abakaliki,
Ebonyi State, Nigeria
Full list of author information is available at the end of the article
© 2016 Ukwaja et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Ukwaja et al. Infectious Diseases of Poverty  (2016) 5:39 
DOI 10.1186/s40249-016-0119-8
Multilingual abstracts
Please see Additional file 1 for translations of the abstract
into the six official working languages of the United
Nations.
Background
Buruli ulcer (BU), a neglected tropical disease, is caused
by Mycobacterium ulcerans. Globally, it is the third most
common mycobacteriosis after tuberculosis and leprosy
[1]. The infection leads to the destruction of skin and
soft tissue, presenting as large ulcers usually on the
limbs. Patients who are not treated early can suffer per-
manent disfigurement and functional disability [1, 2].
Buruli ulcer has been reported in 33 countries in Africa,
the Americas, Asia and the Western Pacific. Most cases
occur in tropical and subtropical regions, except for in
Australia, China and Japan [1, 2]. In West and Central
Africa, Benin, Cameroon, Côte d’Ivoire, Democratic Re-
public of Congo (DRC) and Ghana have reported the
majority of cases [3–7].
The exact mode of transmission of M. ulcerans is still
unknown [1, 2]. Epidemiological studies have shown that
BU is commonly found in populations living near rivers,
swamps and wetlands [1, 2, 8]. In several instances, local
environmental events, such as deforestation, flooding and
building of dams, or agricultural activities such as irriga-
tion, have been associated with the emergence of BU [1, 8].
The risk factors for BU that have been repeatedly identified
include proximity to stagnant or slow-flowing bodies of
water, poor wound care and not wearing protective cloth-
ing (e.g., long-sleeved shirts or shoes) [1, 8]. The probable
role of aquatic insects as reservoirs and vectors of M. ulcer-
ans has been proposed, but is still being debated [1, 8, 9].
Although Nigeria is surrounded by countries with a
high endemicity of BU disease, only few cases have been
reported to date. In 1967, four BU cases were first re-
ported from Benue, Nigeria [10]. This was followed by
24 cases reported from Ibadan, in Oyo state, in 1976
[11]. Based on unofficial reports from some states in
Southern Nigeria, the World Health Organization
(WHO) carried out a rapid assessment in 2006, finding
14 cases with clinically-suspected BU [12]. In addition, a
recent report mentioned that nine M. ulcerans strains
were isolated from patients living in Oyo, Anambra,
Cross River, Enugu, Ebonyi and Ogun states, during
2006 and 2012 [13]. Therefore, to date, 51 cases of BU
have been reported from Nigeria. However, given the
high number of BU patients from Nigeria being treated
in neighbouring countries, such as Benin and Cameroon
[14, 15], there seems to be a discrepancy, likely due to
underreporting and inadequate public health structures
to diagnose and treat the disease in Nigeria.
Furthermore, the WHO reports that there is evidence
that BU disease is gradually increasing in incidence and
that its geographic range is also increasing [16]. Given
that the disease can suddenly appear in a new area
which has previously been disease-free, especially in
poor rural communities in Sub-Saharan Africa and other
developing countries, basic data to help plan effective BU
control activities are urgently needed, but lacking [1, 16].
The main objective of this pilot project was to ascertain
the extent of BU disease in rural communities of Nigeria
and provide an evidence base for a systematic na-
tional response. The specific objectives were to assess
the minimum prevalence of BU and to determine the
epidemiologic characteristics of BU in Ogoja territory,
the target endemic region of the project.
Methods
Study area
The study was conducted in the Ogoja territory of Cross
River State, Nigeria (see Fig. 1). The territory is a trop-
ical rainforest belt surrounded by rivers and swamps.
Cross River State derives its name from the Cross River,
which transcends almost the entire length of the state
and empties into the Atlantic (covering an area of
39,000 km2). The majority of the state’s inhabitants util-
ise the Cross River as source of drinking water, and most
engage in farming of rice, yam and cassava. Three Local
Government Areas (LGAs), i.e. Ogoja, Yala and Bekwarra,
which previously constituted Ogoja territory, were se-
lected as the study sites due to prior notification of BU in
the region [12]. There are 31 communities in the three
LGAs. Ten communities, which constitute about one
third of the population of the three LGAs, were selected
for the survey through simple random sampling, covering
an estimated population of 192,169 people [17]. The study
communities have 12 primary health centres and four
secondary health care facilities, including the St Benedict
Tuberculosis and Leprosy Rehabilitation Hospital Ogoja
(SBHO), which is a private not-for-profit (faith-based)
hospital that serves as a referral centre for tuberculosis
and leprosy control in the whole of Ogoja.
Study design
This was a community-based cross-sectional survey
carried out between May 2012 and April 2013. It was
conducted in two phases: a preparatory, and a case-
finding and management phase. During the first three
weeks of the project (May 2012), advocacy visits were held
with the community leaders and health authorities, and
their approval for the study was obtained. Project staff
members in the facilities were trained on identification of
BU suspects, sample collection, preparation and transpor-
tation. General health workers and doctors working in the
peripheral health facilities in the three study LGAs were
trained on BU symptoms recognition and appropriate
referral.
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The case-finding and management phase involved
intensive advocacy, communication and social mobilisa-
tion. Due to logistical problems, it was not possible to
undertake a door-to-door survey. However, outreach/
sensitisation activities took the form of village hall/
square meetings with the whole community. Community
leaders were informed of the intention to hold outreach
programmes in their community, a date was chosen for
the event, community members were instructed to
gather at the village hall/square, and finally the commu-
nity sensitisation programme was undertaken. This was
done monthly in all study communities. During the sen-
sitisation activities, the communities were informed
about the free BU treatment opportunities at the SBHO.
Case finding formed part of the advocacy, communica-
tion and social mobilisation activities. Screening for BU
disease was done onsite and persons clinically suspected
were referred to the SBHO for evaluation, free labora-
tory investigation and treatment. In addition, traditional
healers in each community were interviewed about
managing individuals with chronic ulcers that have failed
to heal. They were also trained to refer such cases for
evaluation at the SBHO. Individuals suspected to have
BU disease were interviewed about whether they knew
other people who had similar lesions. Such cases were
identified, evaluated and referred to the SBHO. Patients
suspected of having BU disease that were referred to or
presented at the SBHO had their diagnoses clinically
validated by trained physicians to ensure that they
were consistent with the WHO clinical case definitions
[18, 19], and subsequently had other management strat-
egies initiated.
Laboratory confirmation
Laboratory confirmation of clinical BU disease cases
involved taking swabs from ulcerative lesions and fine
needle aspirates from pre-ulcerative lesions, followed by
laboratory testing (microscopy and/or molecular biology)
using the WHO guidelines [18]. Samples were also sent to
the Institute of Tropical Medicine Antwerp and the
Fig. 1 A map of Nigeria showing states where BU has been previously reported, highlighting the Cross River State and the three pilot project LGAs
Ukwaja et al. Infectious Diseases of Poverty  (2016) 5:39 Page 3 of 9
Division of Infectious Diseases and Tropical Medicine,
Medical Centre of The University of Munich, where quan-
titative polymerase chain reaction (qPCR) was performed
for the detection of M. ulcerans.
Clinical care and management
Case management was carried out according to the
WHO recommendations [19]. Each patient received an
eight-week drug treatment (chemotherapy) using the
standard regimen of rifampicin and streptomycin.
Wound dressing for ulcerated cases was an important
component of clinical management. For each patient,
this process continued until the wound had either healed
completely or adequately granulated for skin grafting.
Surgery was part of the ulcer management, as some of
the cases required surgical interventions such as de-
bridement, skin grafting and/or amputation. Physiother-
apy was provided to those who had contractures and
limitation in movement.
Statistical analysis
The data were recorded on a standardised BU report
form, double-entered into a Microsoft Excel (Microsoft
Office Inc for Windows, USA) database and analysed
using Epi Info version 3.4.1 (Centers for Diseases Control
and Prevention, Atlanta, GA, USA). Continuous variables
were summarised as medians (interquartile ranges), and
categorical variables as counts and percentages. The
Fisher’s exact or chi-square test was used to compare
categorical proportions, and the Student’s t-test or
Mann–Whitney U test was used in the case of con-
tinuous variables. The significance level was set at
5 %.
Ethics statement
Ethical approval for this study was obtained from the
Ethical Advisory Board of the German Tuberculosis and
Leprosy Relief Association. Permission was also obtained
from the management of the SBHO. All patients or their
legal guardians (for minors) gave written informed con-
sent for all diagnostic and treatment purposes, as well as
for the publication of clinical photographs. All BU cases
part of the study were treated at no financial costs to
them.
Results
Laboratory confirmation of cases
In the one-year period of the project, 41 patients with
clinical BU lesions at different stages of development
were identified. Of these, 36 (87.8 %) were confirmed by
qPCR. Of the cases not confirmed in the laboratory, four
(9.8 %) tested negative by qPCR and one (2.4 %) didn’t
have samples collected. In addition, 45.2 % (14/31) of
the clinically confirmed BU cases who had a smear
examination also tested positive using Ziehl-Neelsen
staining—all of whom were also positive for BU using
the qPCR method. We restricted our subsequent report
to the 36 cases who were positive for BU by qPCR.
Clinical presentation
All 36 (100 %) patients were newly diagnosed BU disease
cases. About 88.9 % of the lesions were at the ulcerative
stage (see Fig. 2) and 11.1 % were at the pre-ulcerative
stage. Lesions occurring at both the ulcerative and pre-
ulcerative stages were seen in 2.8 % of the patients.
Table 1 shows the clinico-epidemiological features of the
cases. The locations of the lesions were variable: 19
Fig. 2 A typical Buruli ulcer on the upper limb of an adult male identified during the study
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(52.8 %) had lesions on the lower limb, 14 (38.9 %) had
lesions on the upper limb and three (8.3 %) had lesions
on the trunk. More than half (52.8 %; 19) of the patients
presented advanced ulcer lesions that were more than
15 cm in diameter (Category III lesions) (see Fig. 3), the
majority of which occurred in females (58.3 % vs. 41.7 %;
p = 0.35); while 11 (30.6 %) had lesions that were 6–
15 cm in diameter (Category II lesions). In addition, 24
(67 %) had functional limitations in movement, with these
limitations most significantly occurring (58.3 %—14 pa-
tients) in patients with lesions on the lower limb.
Epidemiological features
Using the identified active lesions (pre-ulcerative or
ulcerative) and the populations of the study communi-
ties, we estimated that the crude minimum prevalence
rate was 18.7 per 100, 000. Table 2 shows the minimum
prevalence and distribution of BU disease cases accord-
ing to the size of the population where the survey was
conducted. Ogoja LGA had the highest prevalence rate
of 41.4 per 100,000 population. Of the PCR-confirmed
BU cases, 24 (66.7 %) were female and 12 (33.3 %)
were male. The ages of the patients ranged from four
to 60 years (median: 17 years, mode: 20 years). Over-
all, 15 (41.7 %) were children (≤15 years). No statis-
tical difference was observed in terms of sex among
patients who were children (≤15 years) compared
with adults >15 years old (Fisher’s exact test: p = 0.14)
(see Table 1).
The distribution of lesions on the limbs and trunk did
not differ among the sexes (χ2 = 1.4; p = 0.24). Among
females, lesions occurred equally (45.8 %) on the upper
limb and the lower limb, while the remaining 8.4 % oc-
curred on the trunk. Among males, 66.7 % of the lesions
occurred on the lower limb, 25.0 % on the upper limb
and 8.3 % on the trunk. The distribution of the lesions
also did not differ by age group (Fisher’s exact test: p =
0.455). Among children, 53.3 % of the lesions occurred
on the lower limb, 40 % on the upper limb and 6.7 % on
the trunk. Among adults, 52.4 % of lesions occurred on
the lower limb, 38.1 % on the upper limb and 9.5 % at
the trunk.
Case management
Of the cases diagnosed, 35 were treated with antibiotics
(oral rifampicin and streptomycin injection) for eight
weeks, while one patient declined treatment. Of the
treated cases, 29 (82.9 %) needed and received surgery.
All 35 treated cases completed treatment and were dis-
charged. Figure 4 shows the progression of one case’s
healing process. Of the total number of cases, 29
(82.9 %) healed with some limitations in movement,
while six (17.1 %) cases healed with no limitation in
movement. Healing with limitations in movement oc-
curred in 18/19 (94.7 %), 8/10 (80.0 %) and 3/6
(50 %) of patients with Category III (>15 cm), Category II
(6–15 cm) and Category I (≤5 cm) lesions, respectively
(see Fig. 5). All the cases that healed with limitations in
joint movement received physiotherapy, with some im-
provements observed. Overall, the treatment duration (in-
cluding hospitalisation/dressings) ranged from 56 to 244
(median of 135) days. Patients with Category III, II and I
lesions had median durations of treatment of 120, 116 and
83, days, respectively (p = 0.37). The median duration of
treatment was 130 (87–164) days for children and 98
(56–134) days for adults (p = 0.15).
Discussion
The overall crude prevalence rate of BU of 18.7 per
100,000 in the study communities (and the much higher
rate of 41.4 per 100,000 in Ogoja) indicates that BU is
prevalent in the region, and particularly in Ogoja terri-
tory. Before this pilot project, a cumulative total of 51
BU cases have been reported from Nigeria [15]—only
three of these were from Ogoja LGA [12]. This suggests
that in endemic communities in Nigeria, the number of
BU cases is grossly underestimated. Therefore, there is
an urgent need to step up BU case finding in communi-
ties where standard reporting has previously identified at
least one BU case. The crude prevalence rate of BU
found in this study is comparable to the 21 and 30 per
100,000 cases found in nationwide surveys in Ghana and
Cote d’Ivoire, respectively [6, 7]. However, our finding
Table 1 Clinico-epidemiological features of Buruli ulcer cases in
Ogoja territory, May 2012 to April 2013
Characteristics Buruli ulcer case n (%)
Sex Female 24 (66.7)
Male 12 (33.3)
Age group ≤15 years 15 (41.7)
>15 years 21 (58.3)
Classification of cases New case 36 (100)
Recurrent 0 (0)
Clinical form Plaque 4 (11.1)
Ulcer 31 (86.1)
Ulcer and oedema 1 (2.8)
Site of lesion Upper limb 14 (38.9)
Lower limb 19 (52.8)
Trunk 3 (8.3)
Size of lesion Category I 6 (16.7)
Category II 11 (30.6)
Category III 19 (52.8)
Limitation of movement? Yes 24 (66.7)
No 12 (33.3)
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was lower than 184, 205 and 330 per 100,000 population
reported in a district in Benin, Cameroon and DRC, re-
spectively [5, 14, 20, 21]. In our current effort, we have
probably missed several prevalent BU cases that would
have been identified if more active case-finding activities
were implemented. Although BU is a notifiable disease
in Nigeria, there have not been any deliberate efforts to
engage the affected communities to identify and treat
the disease. One of the commonly held notions by heath
policymakers in Nigeria is that BU disease is not en-
demic in the country. The findings of this study disagree
with this belief and justify the need for the institution of
deliberate efforts to identify and control BU.
The median age of cases in this study was comparable
to patients aged 15.5 years, as reported from Cameroon
[20]. It was lower than the median age observed in
Ghana (25 years) and DRC (27 years), but higher than
the median age of 12 years reported in Benin [5, 6, 22].
Overall, our study agrees with previous studies that
found that the highest rate of the disease is observed
among children <15 years of age in disease-endemic
communities [5–7, 21, 22]. In addition, we found that
>60 % of cases occurred in females. Previous studies didn’t
observe any statistical differences in the occurrence of
cases among the sexes [3, 6, 14, 22]. This difference may
be attributable to a higher proportion of females partici-
pating in sensitisation and project activities in the com-
munities, and therefore those with lesions had a higher
likelihood to be screened and assessed, as census data sug-
gest no female sex dominance in the population [17].
About 92 % of the BU cases had lesions on their
extremities in our study. This is consistent with observa-
tions in Ghana, Côte d’Ivoire and DRC, which found
that more than 90 % of the lesions occur on the limbs
[5–7]. Females had an equal number of lesions on the
upper and lower limbs, while males predominantly had
lesions on the lower limbs. The reason/s for this differ-
ence is not clear, but this finding is consistent with the
findings of Barker [23]. However, recent surveys have
observed no differences among the sexes in the distribu-
tion of lesions [3, 6, 14].
The most common clinical presentation was an ulcera-
tive lesion, which occurred in almost 90 % of the cases.
Fig. 3 Distribution and sizes of Buruli ulcer lesions, according to patients’ sex
Table 2 Prevalence of Buruli ulcer in the Ogoja territory, May







Bekwarra 1 41,623 3 7.2
Ogoja 7 67,614 28 41.4
Yala 2 82,932 5 6.0
Total
population
10 192,169 36 18.7
Ukwaja et al. Infectious Diseases of Poverty  (2016) 5:39 Page 6 of 9
This agrees with studies conducted in the DRC, Cote
d’Ivoire and Cameroon [4, 5, 7, 14]; while the proportion
of patients with ulcerative lesions was lower in previous
surveys undertaken in Ghana and Benin, which recorded
proportions of ulcerative lesions ranging from 48 % to
58 % [3, 6, 21]. Furthermore, two-thirds (67 %) of the
cases had functional limitations of joint movement at
presentation. This contrasts with previous findings
which show that this occurs in less than one third of
cases in other African endemic regions [5, 20]. This may
be because more than half of the BU cases in this study
had Category III lesions and were prone to complica-
tions. Moreover, late presentation due to a lack of BU
control activities in Nigeria may have contributed to
BU-related complications, resulting in a high proportion
of cases with limitations of joint movement. Previous re-
views have suggested an equal distribution of Category I,
II, and III lesions [1]. The higher proportion of Category
Fig. 4 Progressive healing of a Buruli ulcer patient who was given treatment
Fig. 5 Proportion of healed Buruli ulcer cases with or without limitation in movement, according to size of the lesion
Ukwaja et al. Infectious Diseases of Poverty  (2016) 5:39 Page 7 of 9
III lesions observed in this study may partly be explained
by the study design, which focused on finding individ-
uals with chronic ulcers in the community.
In addition, the identification of patients with more
advanced ulcerative lesions may have allowed easier
quality sample collection, which contributed to the high
rate of laboratory confirmation of clinical cases. Most
studies in other endemic regions in Africa had rates of
laboratory-confirmed BU cases ranging from 30 % to
74 % [24–27]. Thus, the high rate of laboratory-confirmed
cases in this survey may reflect a higher endemicity of
active BU cases in the study communities than was previ-
ously observed. Moreover, given that only relatively few
cases had Category I and II lesions, future surveys should
target households, in order to increase the detection, diag-
nosis and treatment of individuals with early BU lesions in
the community. Also, project staff and general health
workers should be trained to identify early lesions of BU
(i.e. oedema, nodules, etc.).
All treated BU cases completed chemotherapy and
none were lost to follow-up. This reflects the effective-
ness of the project in retaining cases and is comparable
to other studies that showed high rates of successful out-
comes of treated BU cases [24, 27]. The free treatment
and socio-economic support provided by the project to
the patients may have contributed to the success of the
disease management. A previous study showed that even
accessing highly-subsidised BU treatment programmes
was challenging for patients, leading to many of them
abandoning biomedical treatment altogether [28]. Future
BU control projects in Nigeria will benefit from adopting
the lessons learnt from the successes of this project.
A gap in our study is the lack of data on the HIV
status of patients. In any case, there is little evidence
from literature that there is an association between HIV
and BU [29]. Secondly, unlike other studies in BU en-
demic settings [5–7], we adopted a strategy that combined
different methods to detect the cases; a door-to-door sur-
vey may have yielded more cases.
Conclusion
In conclusion, this study has a number of strengths,
including that it confirmed the endemicity of BU in the
study population. We also identified—for the first
time—more cases of clinical and laboratory-confirmed
BU in Nigeria compared to any period in the past, as
previous cases have not been sought. In addition, all
treated cases completed chemotherapy. This study
shows that BU disease is endemic in Ogoja territory of
Cross River State and that the burden of the disease is
likely to have been grossly underestimated in Nigeria. In
all areas where BU has been reported in the last decade,
the burden of the disease may be substantially higher than
currently documented through the routine reporting
system. We recommend that a phased systematic nation-
wide response based on lessons learnt from the pilot BU
control programme be established—this may be inte-
grated with National Tuberculosis and Leprosy Control
Programme. We also believe that the identification and
mapping of BU endemic regions in Nigeria should be
strengthened.
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